New Stock News | True Health Company's Hong Kong IPO and domestic unlisted shares "fully circulated" approved by China Securities Regulatory Commission

On May 29, the International Cooperation Department of the China Securities Regulatory Commission issued a notice regarding the overseas issuance and listing of Guangdong Zhenjiankang Medical Technology Development Co., Ltd. and the "full circulation" filing of unlisted shares domestically. Zhenjiankang Company plans to issue no more than 9,223,600 overseas listed common shares and list on the Hong Kong Stock Exchange. 35 shareholders of the company intend to convert a total of 32,082,303 unlisted domestic shares into overseas listed shares and list them for circulation on the Hong Kong Stock Exchange. According to the information, Guangdong Zhenjiankang Medical Technology Development Co., Ltd. (hereinafter referred to as "Zhenjiankang Company") is a national high-tech enterprise focusing on the development and industrialization of soft tissue puncture diagnosis and treatment, organ repair, and intelligent Siasun Robot & Automation with artificial intelligence and Siasun Robot & Automation control as core technologies. It is a national-level specialized and new innovative "small giant" enterprise, a unicorn enterprise with potential for cooperation in the region, one of the first "listed reserve enterprises," and one of the first "cultivating excellence" enterprises.